News & Press
Follow our news to learn how Dermagnostix is redefining molecular diagnostics in dermatology with our point-of-need microfluidics platform.
Subscribe to our newsletter!
News
Next Generation Pathology – Dermagnostix at the DGP Annual Meeting in Munich
“We need this test in our lab!” – it’s hard to imagine a better welcome from a visitor to our booth. Even though we were serving a niche with dermatopathology at the 107th Annual Meeting of the German Society of Pathology (DGP), we were even more pleased about the enthusiasm shown by our booth visitors.
Dermagnostix expands US business development by Eureka Innowwide funding and acceptance into German Accelerator
By participating in several conferences and trade shows in the US – most recently at the ISDP meeting in San Diego – Dermagnostix has already been able to show that the interest in PsorX is high and the feedback is consistently positive. In 2024, the focus will shift even more to business development in the USA. The
DX featured at Kompass Dermatologie
Dermagnostix is featured in the journal series ‘Karger Kompass’ aimed at clinicians and specialists in private practice with a focus on young, committed physicians with four specialist target groups of pneumologists, dermatologists, oncologists and ophthalmologists.
Press information
Dermagnostix is a young medtech company redefining molecular diagnostics in dermatology based on a cutting-edge point-of-need microfluidics platform. Our goal is to help patients around the globe get accurate, timely diagnoses.
Dermagnostix GmbH announces product launch of PsorX®-LabDisk (CE-IVD) after successful pilot customer phase
Dermagnostix announces the official launch of the PsorX®-LabDisk. After the market entry with CE-IVD certification in 2022 and a following successful pilot customer phase, the innovative molecular test for the differential diagnosis of psoriasis and eczema was officially launched in June 2024. The Dermagnostix system consisting of the LabDisk-Analyzer, LabDisk and the Connectivity Solution marks
Dermagnostix announces PsorX-LabDisk as their first CE-IVD
Dermagnostix announces PsorX LabDisks are now CE-IVD test kits in Germany. PsorX is a first in-class molecular test to support differential diagnosis of psoriasis and eczema or atopic dermatitis. PsorX two-gene classifier accurately and efficiently distinguishes psoriasis from eczema, even in cases where conventional diagnostic methods have failed.
Dermagnostix achieves EN ISO 13485:2016 certification
Dermagnostix proudly announces completion of ISO certification. Dermagnostix passed Stage 1 of ISO certification in May, 2022 and was recommended for Stage 2. In December we fully qualified our products for market entry and passed stage 2 to complete the certification of Dermagnostix and implementation of PsorX in a fully automated miniature laboratory for minimally
Dermagnostix announces commercial pilot of PsorX-LabDisk
Dermagnostix announces the commercial pilot of PsorX LabDisks as CE-IVD test kits in Germany. PsorX is a first in-class molecular test for differential diagnosis of psoriasis and eczema or atopic dermatitis. PsorX two-gene classifier accurately and efficiently distinguishes psoriasis from all forms of eczema, even in cases where conventional diagnostic methods have failed.
Dermagnostix announces CE-IVD mark for PsorX-LabDisk and LabDisk-Analyzer
Dermagnostix announces CE-IVD mark for PsorX LabDisk and LabDisk-Analyzer. CE-IVD mark for PsorX provides our customers with the knowledge and assurance that our point of need solution is developed with the highest standards for efficacy and safety. “The receipt of the CE-IVD mark is an important milestone for Dermagnostix as we move towards commercialization. It